Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: There is currently an explosion in the number of so-called targeted therapies. As new indications for these agents multiply, there is also an increase of new and less new side-effects. RECENT FINDINGS: Given this rapidly evolving field, any literature on that topic is rapidly obsolete and needs re-evaluation. SUMMARY: Targeted therapies are associated with a wide spectrum of adverse events, which cannot always be easily separated from the complications linked to cancer, its therapy, and comorbidities. A high awareness of these events might improve the patient's quality of life and contribute to the recognition of new syndromes.
No takes yet. Share an insight, caveat, or question.
Jean Klášterský (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: